Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 18/20 | 0.60 |
| ▸ | ESR2 | Q92731 | 18/20 | 0.60 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.54 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.54 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.54 |
| ▸ | GCGR | P47871 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7105337 | 0.99 | ESR1 (0.60) | ESR1ESR2PSMB1PSMB5PSMB2 | |
| SCHEMBL8582272 | 0.99 | ESR1 (0.58) | ESR1ESR2PSMB1PSMB5PSMB2 | |
| SCHEMBL8477243 | 0.96 | ESR1 (0.56) | ESR1ESR2PSMB1PSMB5PSMB2 | |
| SCHEMBL8478697 | 0.96 | ESR1 (0.56) | ESR1ESR2PSMB1PSMB5PSMB2 | |
| SCHEMBL8476393 | 0.95 | KDM4E (0.56) | ESR1ESR2GCGR | |
| SCHEMBL8473117 | 0.95 | ESR1 (0.62) | ESR1ESR2 | |
| SCHEMBL8476813 | 0.94 | ESR1 (0.63) | ESR1ESR2 | |
| SCHEMBL8472976 | 0.94 | GCGR (0.61) | ESR1ESR2PSMB1PSMB5PSMB2 | |
| SCHEMBL11186372 | 0.94 | ESR1 (0.61) | ESR1ESR2PSMB1PSMB5PSMB2 | |
| SCHEMBL11184205 | 0.93 | ESR1 (0.59) | ESR1ESR2PSMB1PSMB5PSMB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6599920-B2 | Antiestrogenic compound having fewer or no estrogen agonist properties on reproductive tissues | ELI LILLY AND COMPANY | 2003-07-29 | — | — | US | disclosed |
| US-20030100754-A1 | NAPHTHALENE COMPOUNDS, INTERMEDIATES, FORMULATIONS, AND METHODS | ELI LILLY AND COMPANY | 2003-05-29 | — | — | US | disclosed |
| EP-0826670-B1 | Naphthalene compounds, intermediates, formulations, and methods | LILLY CO ELI (US) | 2002-05-08 | — | — | EP | disclosed |
| US-5958916-A | FOR INHIBITING BONE LOSS OR BONE RESORPTION | ELI LILLY AND COMPANY (US) | 1999-09-28 | — | — | US | disclosed |
| EP-0826670-A1 | Naphthalene compounds, intermediates, formulations, and methods | ELI LILLY AND COMPANY (US) | 1998-03-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100754-A1 | NAPHTHALENE COMPOUNDS, INTERMEDIATES, FORMULATIONS, AND METHODS | NDC1, SQLE, NQO1 | ESR1 1044/4885ESR2 2130/4885PSMB1 3230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.